| Literature DB >> 31602083 |
Saeed A Mahmood1, Omaima S Mahmood2, Ayman A El-Menyar3,4, Mohammad M Asim3, Ahmed Abdel-Aziz Abdelbari2, Talat Saeed Chughtai1, Hassan A Al-Thani1.
Abstract
BACKGROUND: Self-extubation is a common clinical problem associated with mechanical ventilation in trauma patients worldwide.Entities:
Keywords: Agitation; head injury; sedation; self-extubation; trauma intensive care unit
Year: 2019 PMID: 31602083 PMCID: PMC6775851 DOI: 10.4103/aer.AER_92_19
Source DB: PubMed Journal: Anesth Essays Res ISSN: 2229-7685
STROBE Statement—checklist of items that should be included in reports of observational studies
| Item no | Recommendation | |
|---|---|---|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract Page 1,2,3 |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2,3 | ||
| Introduction | ||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported Pages 4 and 5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses Page 5 |
| Methods | ||
| Study design | 4 | Present key elements of study design early in the paper Page 5-6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 5-6 |
| Participants | 6 | (a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants Page 5-6 |
| (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case Not applicable | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 5-6, tables, fig |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 5-6 |
| Bias | 9 | Describe any efforts to address potential sources of bias Page 6-7 |
| Study size | 10 | Explain how the study size was arrived at Page 6 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 6,7 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding Page 6,7 |
| (b) Describe any methods used to examine subgroups and interactions Tables &figures | ||
| (c) Explain how missing data were addressed 7 | ||
| (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy | ||
| (e) Describe any sensitivity analyses Tab&fig | ||
| Results | ||
| Participants | 13* | (a) Report numbers of individuals at each stage of study - e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
| (b) Give reasons for non-participation at each stage | ||
| (c) Consider use of a flow diagram Page 7 &8 figure | ||
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
| (b) Indicate number of participants with missing data for each variable of interest | ||
| (c) Cohort study - Summarise follow-up time (eg, average and total amount) Page 7-8 | ||
| Outcome data | 15* | Cohort study - Report numbers of outcome events or summary measures over time |
| Case-control study - Report numbers in each exposure category, or summary measures of exposure | ||
| Cross-sectional study - Report numbers of outcome events or summary measures Page 7-9 | ||
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
| (b) Report category boundaries when continuous variables were categorized | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Page 7-9 | ||
| Other analyses | 17 | Report other analyses done - e.g., analyses of subgroups and interactions, and sensitivity analyses |
| Discussion | ||
| Key results | 18 | Summarise key results with reference to study objectives Pages 9-14 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 14 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Pages 9-14 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results Pages 9-14 |
| Other information | ||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Not Applicable |
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
Comparison of demographics, mechanism of injury, and brain lesions among intubated traumatic brain injury patients admitted to trauma intensive care unit by extubation status
| Overall ( | Planned extubation ( | Self-extubation* ( | ||
|---|---|---|---|---|
| Age | 32.3±13.6 | 31.6±13.5 | 37.3±12.9 | 0.01 |
| Males | 301 (93.8) | 264 (93.6) | 37 (94.9) | 0.76 |
| Qatari nationals | 62 (19.3) | 53 (18.8) | 9 (23.1) | 0.52 |
| Mechanism of injury | ||||
| Traffic accidents | 216 (67.3) | 193 (68.4) | 23 (59.0) | 0.69 for all |
| Fall from height | 78 (24.3) | 66 (23.4) | 12 (30.8) | |
| Fall of heavy object | 8 (2.5) | 6 (2.1) | 2 (5.1) | |
| Assault | 7 (2.2) | 6 (2.1) | 1 (2.6) | |
| All-terrain vehicles | 4 (1.2) | 4 (1.4) | 0 | |
| Others | 8 (2.5) | 7 (2.5) | 1 (2.6) | |
| TBI lesions | ||||
| Brain contusion | 208 (64.8) | 186 (66.0) | 22 (56.4) | 0.24 |
| Skull fracture | 198 (61.7) | 175 (62.1) | 23 (59.0) | 0.71 |
| Subdural hemorrhage | 127 (39.6) | 108 (38.3) | 19 (48.7) | 0.21 |
| Subarachnoid hemorrhage | 126 (39.3) | 110 (39.0) | 16 (41.0) | 0.80 |
| Brain edema | 119 (37.1) | 106 (37.6) | 13 (33.3) | 0.60 |
| Epidural hematoma | 66 (20.6) | 59 (20.9) | 7 (17.9) | 0.66 |
| Diffuse axonal injury | 67 (20.9) | 55 (19.5) | 12 (30.8) | 0.10 |
| Pneumocephalus | 48 (15.0) | 43 (15.2) | 5 (12.8) | 0.81 |
| Intraventricular hemorrhage | 44 (14.7) | 42 (14.9) | 2 (5.1) | 0.13 |
| Extra-axial hemorrhage | 20 (6.2) | 17 (6.0) | 3 (7.7) | 0.72 |
| Intracerebral hemorrhage | 5 (1.6) | 5 (1.8) | 0 | 1.00 |
| Tracheostomy | 92 (28.7) | 82 (29.1) | 10 (25.6) | 0.65 |
| Agitation | 29 (9.0) | 9 (3.2) | 20 (51.3) | 0.001 |
| Physical restraints | 58 (18.1) | 30 (10.7) | 28 (71.8 ) | 0.001 |
*12 patients had reintubation. TBI=Traumatic brain injury
Figure 1Proportion of self-extubation according to the type of head injury lesion
Management and outcomes among traumatic brain injury patients by extubation status
| Overall ( | Planned extubation ( | Self-extubation ( | ||
|---|---|---|---|---|
| GCS ICU | 9.1±3.7 | 8.9±3.9 | 10.1±1.1 | 0.001 |
| Head AIS | 4 (1-9) | 4 (1-9) | 4 (2-5) | 0.94 |
| Injury severity score | 27 (5-75) | 27 (9-75) | 29 (5-50) | 0.77 |
| Ramsay sedation score | 1 (1-5) | 1 (1-2) | 2 (1-5) | 0.01 |
| PEEP level | 5.5±0.7 | 5.6±0.9 | 5.2±0.4 | 0.04 |
| Tramadol, | 16 (5.0) | 4 (1.4) | 12 (30.8) | 0.001 |
| Analgesics ( | ||||
| Fentanyl | 214 (84.6) | 178 (83.2) | 36 (92.3) | 0.22 for all |
| Remifentanil | 39 (15.4) | 36 (16.8) | 3 (7.7) | |
| Sedatives ( | ||||
| Propofol | 176 (72.1) | 140 (68.3) | 36 (92.3) | 0.001 for all |
| Midazolam | 68 (27.9) | 65 (31.7) | 3 (7.7) | |
| ICU length of stay (days) | 19 (5-163) | 19 (5-163) | 19 (9-79) | 0.23 |
| Ventilatory days | 12 (5-47) | 12.5 (5-47) | 13 (5-44) | 0.24 |
| Hospital length of stay | 31 (5-361) | 30 (5-361) | 36 (15-157) | 0.03 |
| Complications, | ||||
| Pneumonia | 181 (56.4) | 154 (54.6) | 27 (69.2) | 0.08 |
| ARDS | 27 (8.4) | 23 (8.2) | 4 (10.3) | 0.65 |
| Sepsis | 72 (22.4) | 56 (19.9) | 16 (41.0) | 0.003 |
| Mortality, | 70 (21.8) | 69 (24.5) | 1 (2.6) | 0.001 |
PEEP=Positive end-expiratory pressure, GCS=Glasgow Coma Scale, ICU=Intensive care unit, AIS=Abbreviated injury score, ARDS=Acute respiratory distress syndrome
Univariate and multivariate analysis for predictors of self-extubation
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | aOR | 95% CI | |||
| Sedation | 0.179 | 0.053-0.604 | 0.006 | 0.060 | 0.011-0.325 | 0.001 |
| Agitation | 31.93 | 12.803-79.631 | 0.001 | 3.435 | 0.997-11.831 | 0.051 |
| Restrain use | 21.29 | 9.631-47.094 | 0.001 | 10.363 | 3.164-33.948 | 0.001 |
| GCS at ICU | 1.08 | 0.987-1.200 | 0.080 | 0.94 | 0.766-1.168 | 0.60 |
| Tramadol use | 30.88 | 9.317-102.408 | 0.001 | 7.21 | 1.461-35.589 | 0.015 |
| Age | 1.03 | 1.005-1.049 | 0.02 | |||
OR=Odds ratio, Age - aOR=Adjusted OR, CI=Confidence interval, GCS=Glasgow Coma Scale, ICU=Intensive care unit